Rajbir Singh to Antihypertensive Agents
This is a "connection" page, showing publications Rajbir Singh has written about Antihypertensive Agents.
Connection Strength
0.076
-
Eadon MT, Cavanaugh KL, Orlando LA, Christian D, Chakraborty H, Steen-Burrell KA, Merrill P, Seo J, Hauser D, Singh R, Beasley CM, Fuloria J, Kitzman H, Parker AS, Ramos M, Ong HH, Elwood EN, Lynch SE, Clermont S, Cicali EJ, Starostik P, Pratt VM, Nguyen KA, Rosenman MB, Calman NS, Robinson M, Nadkarni GN, Madden EB, Kucher N, Volpi S, Dexter PR, Skaar TC, Johnson JA, Cooper-DeHoff RM, Horowitz CR. Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension. Contemp Clin Trials. 2022 08; 119:106813.
Score: 0.039
-
Cooper-DeHoff RM, Fontil V, Carton T, Chamberlain AM, Todd J, O'Brien EC, Shaw KM, Smith M, Choi S, Nilles EK, Ford D, Tecson KM, Dennar PE, Ahmad F, Wu S, McClay JC, Azar K, Singh R, Faulkner Modrow M, Shay CM, Rakotz M, Wozniak G, Pletcher MJ. Tracking Blood Pressure Control Performance and Process Metrics in 25 US Health Systems: The PCORnet Blood Pressure Control Laboratory. J Am Heart Assoc. 2021 11 02; 10(21):e022224.
Score: 0.037